ABSTRACT Studies have suggested involvement of interleukin 17 (IL-17) in autoimmune diseases, although its effect on B cell biology has not been clearly established. Here we demonstrate that

IL-17 alone or in combination with B cell–activating factor controlled the survival and proliferation of human B cells and their differentiation into immunoglobulin-secreting cells. This

effect was mediated mainly through the nuclear factor-κB-regulated transcription factor Twist-1. In support of the relevance of our observations and the potential involvement of IL-17 in B

cell biology, we found that the serum of patients with systemic lupus erythematosus had higher concentrations of IL-17 than did the serum of healthy people and that IL-17 abundance

Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn

about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS LOW-DOSE IL-2 ENHANCES THE GENERATION OF IL-10-PRODUCING IMMUNOREGULATORY

B CELLS Article Open access 12 April 2023 THE SURVIVAL AND FUNCTION OF IL-10-PRODUCING REGULATORY B CELLS ARE NEGATIVELY CONTROLLED BY SLAMF5 Article Open access 25 March 2021 TOLL-LIKE

RECEPTOR SIGNALLING IN B CELLS DURING SYSTEMIC LUPUS ERYTHEMATOSUS Article 18 December 2020 CHANGE HISTORY * _ 12 JULY 2013 Despite many attempts to replicate these results, the authors have

been unable to confirm the original data showing that IL-17 alone or in combination with B cell–activating factor controls the survival of human B cells (FIG. 1A,B). Because this weakens

the conclusions of the paper, all the authors (except A.D. and P.T., who could not be contacted) now retract this paper. _ REFERENCES * Yurasov, S., Hammersen, J., Tiller, T., Tsuiji, M.

& Wardemann, H. B-cell tolerance checkpoints in healthy humans and patients with systemic lupus erythematosus. _Ann. NY Acad. Sci._ 1062, 165–174 (2005). Article  CAS  Google Scholar  *

Meffre, E. & Wardemann, H. B-cell tolerance checkpoints in health and autoimmunity. _Curr. Opin. Immunol._ 20, 632–638 (2008). Article  CAS  Google Scholar  * Groom, J. & Mackay, F.

B cells flying solo. _Immunol. Cell Biol._ 86, 40–46 (2008). Article  CAS  Google Scholar  * Nagata, S. & Golstein, P. The Fas death factor. _Science_ 267, 1449–1456 (1995). Article  CAS

  Google Scholar  * Nagata, S. & Suda, T. Fas and Fas ligand: lpr and gld mutations. _Immunol. Today_ 16, 39–43 (1995). Article  CAS  Google Scholar  * Hutcheson, J. et al. Combined

deficiency of proapoptotic regulators Bim and Fas results in the early onset of systemic autoimmunity. _Immunity_ 28, 206–217 (2008). Article  CAS  Google Scholar  * Rieux-Laucat, F., Le

Deist, F. & Fischer, A. Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways. _Cell Death Differ._ 10, 124–133 (2003). Article  CAS  Google Scholar  * Andre,

J. et al. Overexpression of the antiapoptotic gene Bfl-1 in B cells from patients with familial systemic lupus erythematosus. _Lupus_ 16, 95–100 (2007). Article  CAS  Google Scholar  *

Batten, M. et al. BAFF mediates survival of peripheral immature B lymphocytes. _J. Exp. Med._ 192, 1453–1466 (2000). Article  CAS  Google Scholar  * Hsu, B.L., Harless, S.M., Lindsley, R.C.,

Hilbert, D.M. & Cancro, M.P. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. _J. Immunol._ 168, 5993–5996 (2002). Article  CAS  Google

Scholar  * Cheema, G.S., Roschke, V., Hilbert, D.M. & Stohl, W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. _Arthritis

Rheum._ 44, 1313–1319 (2001). Article  CAS  Google Scholar  * Zhang, J. et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. _J. Immunol._ 166, 6–10

(2001). Article  CAS  Google Scholar  * Stohl, W. et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. _Arthritis Rheum._

48, 3475–3486 (2003). Article  Google Scholar  * Pene, J. et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. _J. Immunol._ 180, 7423–7430

(2008). Article  CAS  Google Scholar  * Pan, H.F., Ye, D.Q. & Li, X.P. Type 17 T-helper cells might be a promising therapeutic target for systemic lupus erythematosus. _Nat. Clin. Pract.

Rheumatol._ 4, 352–353 (2008). Article  CAS  Google Scholar  * Wong, C.K. et al. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for

Th17-mediated inflammation in auto-immunity. _Clin. Immunol._ 127, 385–393 (2008). Article  CAS  Google Scholar  * Garrett-Sinha, L.A., John, S. & Gaffen, S.L. IL-17 and the Th17 lineage

in systemic lupus erythematosus. _Curr. Opin. Rheumatol._ 20, 519–525 (2008). Article  CAS  Google Scholar  * Wong, C.K., Ho, C.Y., Li, E.K. & Lam, C.W. Elevation of proinflammatory

cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. _Lupus_ 9, 589–593 (2000). Article  CAS  Google Scholar  * Crispin, J.C.

et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. _J. Immunol._ 181, 8761–8766 (2008). Article  CAS  Google

Scholar  * Kang, H.K., Liu, M. & Datta, S.K. Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T

cells and contraction of inflammatory Th17 cells. _J. Immunol._ 178, 7849–7858 (2007). Article  CAS  Google Scholar  * Hsu, H.C. et al. Interleukin 17-producing T helper cells and

interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. _Nat. Immunol._ 9, 166–175 (2008). Article  CAS  Google Scholar  * Jacob, N. et al. Accelerated

pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway. _J.

Immunol._ 182, 2532–2541 (2009). Article  CAS  Google Scholar  * Lai Kwan Lam, Q., King Hung Ko, O., Zheng, B.J. & Lu, L. Local BAFF gene silencing suppresses Th17-cell generation and

ameliorates autoimmune arthritis. _Proc. Natl. Acad. Sci. USA_ 105, 14993–14998 (2008). Article  Google Scholar  * Mackay, F. & Browning, J.L. BAFF: a fundamental survival factor for B

cells. _Nat. Rev. Immunol._ 2, 465–475 (2002). Article  CAS  Google Scholar  * Li, X. Act1 modulates autoimmunity through its dual functions in CD40L/BAFF and IL-17 signaling. _Cytokine_ 41,

105–113 (2008). Article  CAS  Google Scholar  * Stadanlick, J.E. et al. Tonic B cell antigen receptor signals supply an NF-κB substrate for prosurvival BLyS signaling. _Nat. Immunol._ 9,

1379–1387 (2008). Article  CAS  Google Scholar  * Chen, C., Edelstein, L.C. & Gelinas, C. The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-xL . _Mol.

Cell. Biol._ 20, 2687–2695 (2000). Article  Google Scholar  * Zong, W.X., Edelstein, L.C., Chen, C., Bash, J. & Gelinas, C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct

transcriptional target of NF-κB that blocks TNFα-induced apoptosis. _Genes Dev._ 13, 382–387 (1999). Article  CAS  Google Scholar  * Pham, C.G. et al. Upregulation of Twist-1 by NF-κB blocks

cytotoxicity induced by chemotherapeutic drugs. _Mol. Cell. Biol._ 27, 3920–3935 (2007). Article  CAS  Google Scholar  * Maestro, R. et al. Twist is a potential oncogene that inhibits

apoptosis. _Genes Dev._ 13, 2207–2217 (1999). Article  CAS  Google Scholar  * Ishigami, T. et al. Anti-IgM antibody-induced cell death in a human B lymphoma cell line, B104, represents a

novel programmed cell death. _J. Immunol._ 148, 360–368 (1992). CAS  PubMed  Google Scholar  * Ruprecht, C.R. & Lanzavecchia, A. Toll-like receptor stimulation as a third signal required

for activation of human naive B cells. _Eur. J. Immunol._ 36, 810–816 (2006). Article  CAS  Google Scholar  * John, S.A., Clements, J.L., Russell, L.M. & Garrett-Sinha, L.A. Ets-1

regulates plasma cell differentiation by interfering with the activity of the transcription factor Blimp-1. _J. Biol. Chem._ 283, 951–962 (2008). Article  CAS  Google Scholar  * Ansieau, S.

et al. Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. _Cancer Cell_ 14, 79–89 (2008). Article  CAS  Google Scholar  *

Grumont, R.J., Rourke, I.J. & Gerondakis, S. Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. _Genes Dev._ 13,

400–411 (1999). Article  CAS  Google Scholar  * Lee, H.H., Dadgostar, H., Cheng, Q., Shu, J. & Cheng, G. NF-κB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival

signaling in B lymphocytes. _Proc. Natl. Acad. Sci. USA_ 96, 9136–9141 (1999). Article  CAS  Google Scholar  * Sims, G.P. et al. Identification and characterization of circulating human

transitional B cells. _Blood_ 105, 4390–4398 (2005). Article  CAS  Google Scholar  * Ettinger, R., Kuchen, S. & Lipsky, P.E. Interleukin 21 as a target of intervention in autoimmune

disease. _Ann. Rheum. Dis._ 67 Suppl 3, iii83–iii86 (2008). Article  CAS  Google Scholar  * Litinskiy, M.B. et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and

APRIL. _Nat. Immunol._ 3, 822–829 (2002). Article  CAS  Google Scholar  * Vanden Bush, T.J. & Bishop, G.A. TLR7 and CD40 cooperate in IL-6 production via enhanced JNK and AP-1

activation. _Eur. J. Immunol._ 38, 400–409 (2008). Article  CAS  Google Scholar  * Wilker, P.R. et al. Transcription factor Mef2c is required for B cell proliferation and survival after

antigen receptor stimulation. _Nat. Immunol._ 9, 603–612 (2008). Article  CAS  Google Scholar  * Khiem, D., Cyster, J.G., Schwarz, J.J. & Black, B.L. A p38 MAPK-MEF2C pathway regulates

B-cell proliferation. _Proc. Natl. Acad. Sci. USA_ 105, 17067–17072 (2008). Article  CAS  Google Scholar  * Sosic, D., Richardson, J.A., Yu, K., Ornitz, D.M. & Olson, E.N. Twist

regulates cytokine gene expression through a negative feedback loop that represses NF-κB activity. _Cell_ 112, 169–180 (2003). Article  CAS  Google Scholar  * Niesner, U. et al.

Autoregulation of Th1-mediated inflammation by twist1. _J. Exp. Med._ 205, 1889–1901 (2008). Article  CAS  Google Scholar  * Bubier, J.A. et al. A critical role for IL-21 receptor signaling

in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. _Proc. Natl. Acad. Sci. USA_ 106, 1518–1523 (2009). Article  CAS  Google Scholar  * Sasaki, Y. et al. Canonical NF-κB

activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B cell proliferation upon activation. _Immunity_ 24, 729–739 (2006). Article  CAS  Google Scholar  *

Brien, G., Trescol-Biemont, M.C. & Bonnefoy-Berard, N. Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis. _Oncogene_ 26, 5828–5832 (2007). Article 

CAS  Google Scholar  * de Brouwer, A.P., van Bokhoven, H. & Kremer, H. Comparison of 12 reference genes for normalization of gene expression levels in Epstein-Barr virus-transformed

lymphoblastoid cell lines and fibroblasts. _Mol. Diagn. Ther._ 10, 197–204 (2006). Article  CAS  Google Scholar  Download references ACKNOWLEDGEMENTS We thank H. Mitchison and G. Hinkal for

critical reading of the manuscript; C. Delprat and G. Salles for scientific discussions; the laboratory of A. Puisieux (INSERM U590) for anti-Twist-1 as well as the Twist-1- and

Twist-2-related vectors; and C. Bella for cell sorting. Supported by INSERM, UCB Lyon 1, the Arthritis Fondation Courtin (A.D.), the Association pour la Recherche sur le Cancer and the Ligue

Contre le Cancer (07 and 26). AUTHOR INFORMATION Author notes * Alexandre Belot and Jérémy Bastid: These authors contributed equally to this work. AUTHORS AND AFFILIATIONS * Université de

Lyon, Lyon, France Agnès Doreau, Alexandre Belot, Jérémy Bastid, Benjamin Riche, Marie-Claude Trescol-Biemont, Bruno Ranchin, Nicole Fabien, Pierre Cochat, Claire Pouteil-Noble, Pierre

Trolliet, Isabelle Durieu, Jacques Tebib, Berhouz Kassai, Stéphane Ansieau, Alain Puisieux & Nathalie Bonnefoy-Bérard * Institut National de la Santé et de la Recherche Médicale (INSERM)

U851, Lyon, France Agnès Doreau, Marie-Claude Trescol-Biemont, Nicole Fabien & Nathalie Bonnefoy-Bérard * Université Lyon 1, Institut Fédératif de Recherche 128, Lyon, France Agnès

Doreau, Marie-Claude Trescol-Biemont & Nathalie Bonnefoy-Bérard * Centre de Référence des Maladies Rénales Rares, Service de Néphrologie et Rhumatologie Pédiatriques, Hôpital Femme Mère

Enfant, Bron, France Alexandre Belot, Bruno Ranchin & Pierre Cochat * Centre National de la Recherche Scientifique, UMR5239, Oullins, France Alexandre Belot * INSERM U590, Lyon, France

Jérémy Bastid, Stéphane Ansieau & Alain Puisieux * Centre Léon Bérard, Fédération Nationale des Centres de Lutte Contre le Cancer, Lyon, France Jérémy Bastid, Stéphane Ansieau & 

Alain Puisieux * Service de Biostatistique, Lyon, France Benjamin Riche * Service d'Immunologie, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon, France Nicole Fabien *

INSERM U820, Lyon, France Pierre Cochat * Service de Néphrologie, Lyon, France Claire Pouteil-Noble & Pierre Trolliet * Service de Médecine Interne, Lyon, France Isabelle Durieu *

Service de Rhumatologie, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon, France Jacques Tebib * Service de Pharmacologie Clinique, Hôpital L.-Pradel, INSERM CIC201, Epidémiologie

Pharmacologie Investigation Clinique Information Médicale Mère-Enfant, Centre National de la Recherche Scientifique Unité Mixte de Recherche 5558, Centre Hospitalier Universitaire de Lyon,

Lyon, France Berhouz Kassai * Service d'Immunologie, Centre Hospitalier Universitaire de Montpellier, Faculté de Médecine; Université Montpellier 1, Jean-François Eliaou * Université

Montpellier 1, Montpellier, France Jean-François Eliaou Authors * Agnès Doreau View author publications You can also search for this author inPubMed Google Scholar * Alexandre Belot View

author publications You can also search for this author inPubMed Google Scholar * Jérémy Bastid View author publications You can also search for this author inPubMed Google Scholar *

Benjamin Riche View author publications You can also search for this author inPubMed Google Scholar * Marie-Claude Trescol-Biemont View author publications You can also search for this

author inPubMed Google Scholar * Bruno Ranchin View author publications You can also search for this author inPubMed Google Scholar * Nicole Fabien View author publications You can also

search for this author inPubMed Google Scholar * Pierre Cochat View author publications You can also search for this author inPubMed Google Scholar * Claire Pouteil-Noble View author

publications You can also search for this author inPubMed Google Scholar * Pierre Trolliet View author publications You can also search for this author inPubMed Google Scholar * Isabelle

Durieu View author publications You can also search for this author inPubMed Google Scholar * Jacques Tebib View author publications You can also search for this author inPubMed Google

Scholar * Berhouz Kassai View author publications You can also search for this author inPubMed Google Scholar * Stéphane Ansieau View author publications You can also search for this author

inPubMed Google Scholar * Alain Puisieux View author publications You can also search for this author inPubMed Google Scholar * Jean-François Eliaou View author publications You can also

search for this author inPubMed Google Scholar * Nathalie Bonnefoy-Bérard View author publications You can also search for this author inPubMed Google Scholar CONTRIBUTIONS N.B.-B. designed

and supervised the study and wrote the manuscript; A.D. did all experiments presented in Figures 1,2,3,4,5,6 and Supplementary Figures 1,2,3,4,5,6; A.B. did statistical analysis and

collected clinical data in Supplementary Tables 1 and 2; J.B. helped design the Twist-related experiments and wrote the manuscript; M.-C.T.-B. analyzed _BCL2A1_ expression in B cells from

patients with SLE and healthy volunteers; B. Riche did statistical analysis; B. Ranchin, N.F., P.C., C.P.-N., P.T., I.D, J.T. and B.K. recruited patients; and S.A., A.P. and J.-F.E.

contributed to the design and interpretation of experiments and to the editing of the manuscript. CORRESPONDING AUTHOR Correspondence to Nathalie Bonnefoy-Bérard. SUPPLEMENTARY INFORMATION

SUPPLEMENTARY TEXT AND FIGURES Supplementary Figures 1–6, Tables 1–2 and Supplementary Methods (PDF 2734 kb) RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS

ARTICLE Doreau, A., Belot, A., Bastid, J. _et al._ Interleukin 17 acts in synergy with B cell–activating factor to influence B cell biology and the pathophysiology of systemic lupus

erythematosus. _Nat Immunol_ 10, 778–785 (2009). https://doi.org/10.1038/ni.1741 Download citation * Received: 05 March 2009 * Accepted: 16 April 2009 * Published: 31 May 2009 * Issue Date:

July 2009 * DOI: https://doi.org/10.1038/ni.1741 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is

not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative